Biofidelity launches Aspyre Lung Reagents for liquid biopsy samples

Biofidelity, a leader in innovative genomic solutions, has launched the Aspyre Lung Reagents (research use only) for liquid biopsy samples. Aspyre Lung identifies established non-small cell lung cancer (NSCLC) biomarkers in both DNA and RNA from tissue and blood in a single straightforward, four-step workflow and runs on existing qPCR platforms, enabling simple integration into laboratories globally.

Data supporting the launch and a poster, 'Development of a machine learning model for Aspyre Lung (Blood): a new assay for rapid detection of actionable variants from plasma in NSCLC patients' were presented at the Association for Molecular Pathology Annual Meeting & Expo November 19-23, 2024 in Vancouver, Canada.

Additionally, Dr. Jeff Gregg, Biofidelity Vice President of Medical Affairs, hosted an Innovation Spotlight at the AMP Conference entitled: Aspyre Lung: Simplified Genomic Profiling: A faster, simpler, decentralized alternative to NGS. He stated, “An accessible liquid biopsy platform that can be easily validated and implemented in laboratories globally without the need for investment in new equipment and bioinformatics will undoubtedly lead to a fundamental paradigm shift enabling broader access to genomic testing.”

Biofidelity Co-Founder and CEO Dr. Barnaby Balmforth, added, “Until now there has not been an alternative to next-generation sequencing (NGS) to provide fast, simple, decentralized testing for NSCLC biomarkers. Aspyre Lung’s best-in-class performance from tissue and blood coupled with its proven performance with challenging samples makes Simplified Genomic Profiling (SGP) via Aspyre Lung a game-changer for laboratories globally.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>